Company Overview: ONCOSEC

Industry News

14 Dec

OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab

SAN DIEGO, Dec. 14, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (ONCS), a company developing intratumoral cancer immunotherapies, today announced the initiation of patient dosing in PISCES/KEYNOTE-695, the company’s global, multi-center, registration-directed open-label Phase 2b clinical trial. The trial will evaluate the combination of ImmunoPulse® IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid...

Read more

5 Dec

OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer

SAN DIEGO, Dec. 5, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing intratumoral cancer immunotherapies, today announced the promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer. Dr. Twitty joined OncoSec in 2016 as Executive Director of Clinical Science. He will join the executive leadership team and report to Daniel...

Read more

28 Nov

OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform

SAN DIEGO, Nov. 28, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has added two patents to its broad patent portfolio. The first patent, JP06174632, encompasses a device for post-resection electroporation (“EP”) delivery of an agent (including nucleic...

Read more

9 Nov

OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

OncoSec’s Polycistronic Interleukin-12 Immune Modulator (PIIM) DNA Plasmid Vector Enables Simultaneous Delivery of Multiple Complementary Anti-Cancer Agents OncoSec Presents Emerging Preclinical Data Demonstrating its Novel Platform at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting SAN DIEGO, Nov. 9, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing...

Read more

8 Nov

OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients

Updated Phase 2 Efficacy and Durability Findings to Be Presented at the 2017 Society for Immunotherapy of Cancer Annual Meeting OncoSec to Host Analyst and Investor Event During the 2017 Society for Immunotherapy of Cancer Annual Meeting in National Harbor, MD SAN DIEGO, Nov. 8, 2017 /PRNewswire/ — OncoSec Medical Incorporated...

Read more

23 Oct

OncoSec Announces $7.1 Million Registered Direct Offering Priced At-the-Market

SAN DIEGO, Oct. 23, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into definitive purchase agreements with certain accredited investors to purchase 5,270,934 shares of its common stock, at a purchase price per share of $1.34375 in a registered direct offering...

Read more

19 Oct

OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients

Data from Recently Completed Phase 2 Monotherapy and Combination Therapy Studies Presented at the 2017 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research 8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24...

Read more

12 Oct

OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

Additional abstract highlighting preclinical data from OncoSec’s novel multi-gene expression platform SAN DIEGO, Oct. 11, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present updated clinical data from its phase 2 Investigator Sponsored Trial assessing the combination of OncoSec’s investigational therapy, ImmunoPulse® IL-12 (intratumoral...

Read more

12 Oct

OncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research

OncoSec presented at the 2nd Annual Biomarkers & Precision Medicine USA Congress SAN DIEGO, Oct. 12, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new clinical data on ImmunoPulse® IL-12 (intratumoral pIL-12 with electroporation), its lead program focused...

Read more

10 Oct

OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck’s KEYTRUDA® (pembrolizumab)

Enrolling patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy Global study in the U.S. and Australia ImmunoPulse® IL-12 granted Fast Track and Orphan Drug Designation in the U.S. SAN DIEGO, Oct. 10, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (ONCS), a company...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address